Date Title Description PDF
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
23 Feb 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 16 February and 22 February 2024 Download
16 Feb 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 9 February and 15 February 2024 Download
09 Feb 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 2 February and 8 February 2024 Download
02 Feb 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 26 January and 1 February 2024 Download
26 Jan 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 19 January and 25 January 2024 Download

Pages

Date Title Description PDF
07 Nov 2019 Information on P&L ROVI releases the first nine months 2019 results presentation Download
03 Oct 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the third quarter of 2019 Download
05 Sep 2019 Others on business performance and financial information The Company informs about the construction of a second heparin plant in Granada Download
30 Jul 2019 Information on P&L ROVI releases the first half 2019 results presentation Download
30 Jul 2019 Information on P&L ROVI releases the press release related to the first half 2019 financial results Download

Pages